Posted by Michael Wonder on 22 Jun 2018
NICE backs Ocrevus but primary-progressive group kept waiting
22 June 2018 - NICE published a positive final appraisal determination on Friday for Ocrevus (ocrelizumab) to treat people living with relapsing-remitting multiple sclerosis (RRMS).
The NICE has recommended that the UK National Health Service reimburse Roche’s drug for treating RRMS in adults with active disease, defined by clinical or imaging features, when alemtuzumab is contraindicated or otherwise unsuitable.
Ocrevus has been shown to reduce the number of relapses per year by nearly half and slow the risk of progression of the disease compared with current treatment, subcutaneous interferon beta-1a.
